Clinical Trials
435
Active:10
Completed:182
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:8
Phase 2:36
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (263 trials with phase data)• Click on a phase to view related trials
Not Applicable
196 (74.5%)Phase 2
36 (13.7%)Phase 3
15 (5.7%)Phase 1
8 (3.0%)Phase 4
7 (2.7%)Early Phase 1
1 (0.4%)DESIR. Evaluation of the Pre-therapeutic Activity of Dihydropyrimidine dEShydrogenase (DPD) in Patients With Cancer and/or Renal Failure
Not Applicable
Not yet recruiting
- Conditions
- Renal ImpairmentBreast CancerDigestive Cancers
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 742
- Registration Number
- NCT07124403
Botulinum Toxin Injections Into the Salivary Glands of Cerebrospinal Children With Chronic Sialorrhea
Completed
- Conditions
- Chronic SialorrheaChildren, OnlyDroolingBrain InjuriesBotulinum Toxin
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 5
- Registration Number
- NCT07067762
- Locations
- 🇫🇷
University Hospital Jean-Minjoz, Besançon, France
Evaluation of Oral Corticosteroid Therapy in Idiopathic Sudden Unilateral Hearing Loss.
Not Applicable
Not yet recruiting
- Conditions
- Sudden Sensorineural Hearing Loss
- Interventions
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 430
- Registration Number
- NCT07067801
- Locations
- 🇫🇷
CHU de Besançon, Besançon, France
Neutralizing Interferon Type 1 in Hidradenitis Suppurativa
Not Applicable
Not yet recruiting
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Biological: Plasma with neutralizing autoantibodies to Type I Interferons
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 6
- Registration Number
- NCT07067099
- Locations
- 🇫🇷
CHU Besançon, Besançon, France
MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Advanced Biliary Tract Carcinoma
- Interventions
- Procedure: CT-ScanDrug: MP0317 + Gemcitabine + Cisplatine + DurvalumabDrug: Gemcitabine + Cisplatin + Durvalumab
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 75
- Registration Number
- NCT07036380
- Locations
- 🇫🇷
CHU de Besançon, Besancon, France
🇫🇷Centre georges-François Leclerc, Dijon, France
🇫🇷CHU de Grenoble, Grenoble, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 87
- Next
News
No news found